Skip to main content
main-content

16.05.2019 | Original Paper

Proteomic Investigation of Malignant Major Salivary Gland Tumors

Zeitschrift:
Head and Neck Pathology
Autoren:
Veronica Seccia, Elena Navari, Elena Donadio, Claudia Boldrini, Federica Ciregia, Maurizio Ronci, Antonio Aceto, Iacopo Dallan, Antonio Lucacchini, Augusto Pietro Casani, Maria Rosa Mazzoni, Laura Giusti
Wichtige Hinweise
Veronica Seccia and Elena Navari have contributed equally to this work.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Abstract

The purpose of this study was to define the proteome profile of fine needle aspiration (FNA) samples of malignant major salivary gland tumors (MSGT) compared to benign counterparts, and to evaluate potential clinical correlations and future applications. Patients affected by MSGT (n = 20), pleomorphic adenoma (PA) (n = 37) and Warthin’s tumor (WT) (n = 14) were enrolled. Demographic, clinical and histopathological data were registered for all patients. FNA samples were processed to obtain the protein extracts. Protein separation was obtained by two-dimensional electrophoresis (2-DE) and proteins were identified by mass spectrometry. Western blot analysis was performed to validate the 2-DE results. Statistical differences between groups were calculated by the Mann–Whitney U test for non-normal data. Spearman’s rank correlation coefficient was calculated to evaluate correlations among suggested protein biomarkers and clinical parameters. Twelve and 27 differentially expressed spots were found for MSGT versus PA and MSGT versus WT, respectively. Among these, annexin-5, cofilin-1, peptidyl-prolyl-cistrans-isomerase-A and F-actin-capping-alpha-1 were able to differentiate MSGT from PA, WT, and healthy samples. Moreover, STRING analysis suggested cofilin-1 as a key node of protein interactions. Some of the overexpressed proteins are related to some clinical factors of our cohort, such as survival and outcome. Our results suggest potential protein biomarkers of MSGT, which could allow for more appropriate treatment plans, as well as shedding light on the molecular pathways involved.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

★ PREMIUM-INHALT
e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de. Zusätzlich können Sie eine Zeitschrift Ihrer Wahl in gedruckter Form beziehen – ohne Aufpreis.

Weitere Produktempfehlungen anzeigen
Literatur
Über diesen Artikel
  1. Das kostenlose Testabonnement läuft nach 14 Tagen automatisch und formlos aus. Dieses Abonnement kann nur einmal getestet werden.

Neu im Fachgebiet Pathologie

14.03.2019 | Originalien | Ausgabe 2/2019

Medikamentennachweise bei bayerischen Altenheimbewohnern – eine rechtsmedizinische Analyse

Erste Ergebnisse aus Screeninguntersuchungen an Urinproben

07.03.2019 | Mammakarzinom | CME | Ausgabe 2/2019

Update der S3-Leitlinie Mammakarzinom

Was gibt es Neues für Pathologen?

21.02.2019 | Schwerpunkt: Neuropathologie | Ausgabe 2/2019

Neuropathologie der Medulloblastome und anderer embryonaler Tumoren des ZNS

Präzisierung der Diagnostik durch Integration genetischer Marker